Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,151,373 papers from all fields of science
Search
Sign In
Create Free Account
pseudoginsenoside G(1)
Known as:
pseudoginsenoside G1
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Triterpenes
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
NOETHER-LEFSCHETZ THEORY AND QUESTIONS OF SRINIVAS
S. Nollet
2018
Corpus ID: 161049066
Noether-Lefschetz theory surrounds the question of determining when the restriction map from the Picard group of a variety to the…
Expand
2016
2016
Recurrent fever and headache for 12 years
Q. Lu
,
H. Guan
,
D. Zhong
,
Yin-chang Yang
,
L. Cui
2016
Corpus ID: 75225576
患者 男性,33 岁,反复发热、头痛 12 年,于 2007 年 6 月 18 日入院。患者 12 年前(1995 年 5…
Expand
2015
2015
Pseudoginsenoside-F11 inhibits methamphetamine-induced behaviors by regulating dopaminergic and GABAergic neurons in the nucleus accumbens
Kequan Fu
,
Huiyan Lin
,
+4 authors
A. Nitta
Psychopharmacology
2015
Corpus ID: 253744203
Although dependence to methamphetamine (METH) is associated with serious psychiatric symptoms and is a global health and social…
Expand
2015
2015
Flujos bajos en anestesia
José Manuel Portela-Ortiz
,
Christopher Hernández-Cortés
,
Carolina Delgadillo-Arauz
2015
Corpus ID: 161940194
Tal y como lo menciona Mychaskiw G(1): «en la tradicion de que todo lo antiguo es nuevo otra vez», en los ultimos anos el uso de…
Expand
2004
2004
Neuroprotective role of pseudoginsenoside-F11 on activated microgfia induced by lipopolysaccharide
Xiu-liBI
,
Jing-yuYANG
,
Ying-xuDONG
,
LiangYu
,
Chun-fuWU
2004
Corpus ID: 68595428
AIM: In the present study, the neuroprotective effect and its possible molecular mechanisms of pseudoginsenoside-F11 (PF11),a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE